DIVISLAB - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 4.2
| Stock Code | DIVISLAB | Market Cap | 1,80,643 Cr. | Current Price | 6,805 ₹ | High / Low | 7,078 ₹ |
| Stock P/E | 67.8 | Book Value | 629 ₹ | Dividend Yield | 0.44 % | ROCE | 22.4 % |
| ROE | 16.8 % | Face Value | 2.00 ₹ | DMA 50 | 6,510 ₹ | DMA 200 | 6,308 ₹ |
| Chg in FII Hold | 0.21 % | Chg in DII Hold | -0.05 % | PAT Qtr | 756 Cr. | PAT Prev Qtr | 653 Cr. |
| RSI | 59.3 | MACD | 126 | Volume | 1,61,406 | Avg Vol 1Wk | 4,03,199 |
| Low price | 5,636 ₹ | High price | 7,078 ₹ | PEG Ratio | 4.91 | Debt to equity | 0.00 |
| 52w Index | 81.1 % | Qtr Profit Var | 13.3 % | EPS | 98.2 ₹ | Industry PE | 31.6 |
📈 Chart & Trend Analysis: DIVISLAB is trading at ₹6,805, comfortably above its 50 DMA (₹6,510) and 200 DMA (₹6,308), confirming strong bullish momentum. RSI at 59.3 indicates healthy momentum without being overbought. MACD at 126 shows strong positive divergence. Bollinger Bands place price near the upper band, suggesting continued strength but with potential volatility.
🔎 Momentum Signals: Current volume (1.61L) is below the 1-week average (4.03L), showing reduced participation. Short-term momentum remains positive, with resistance near ₹6,950–₹7,050.
🎯 Entry Zone: ₹6,700–₹6,750 (support near DMA cluster)
🚪 Exit Zone: ₹6,950–₹7,050 (resistance zone)
🛑 Stop-Loss: ₹6,600 (below support)
📊 Trend Status: Strongly trending upward; possible consolidation if volumes remain weak.
Positive
- Trading above both 50 DMA and 200 DMA confirms bullish trend.
- Strong ROCE (22.4%) and ROE (16.8%) highlight efficiency.
- Debt-free balance sheet ensures financial stability.
- Quarterly PAT growth (₹756 Cr vs ₹653 Cr) shows earnings improvement.
- FII inflows (+0.21%) reflect foreign investor confidence.
Limitation
- High P/E (67.8) compared to industry PE (31.6) signals overvaluation risk.
- PEG ratio (4.91) suggests growth is already priced in.
- Volume below average indicates weak conviction in breakout.
- DII holdings decreased (-0.05%), showing reduced domestic support.
Company Negative News
- Decline in DII holdings (-0.05%) signals cautious domestic sentiment.
- High valuation multiples may limit upside in near term.
Company Positive News
- Strong quarterly profit growth (+13.3%).
- FII inflows (+0.21%) support sentiment.
- EPS at ₹98.2 provides earnings visibility.
Industry
- Industry PE at 31.6 is much lower than DIVISLAB’s 67.8, highlighting premium valuation.
- Pharmaceutical sector remains resilient, supported by global demand for APIs and formulations.
Conclusion
⚡ DIVISLAB is in a strong uptrend with robust technical momentum and solid fundamentals. Entry near ₹6,700–₹6,750 offers cautious accumulation, with profit exits around ₹6,950–₹7,050. Elevated valuations and reduced volumes warrant disciplined risk management, but long-term prospects remain strong given efficiency and debt-free status.
Would you like me to expand this into a pharma sector overlay comparing peers like Sun Pharma and Cipla, or keep it focused as a single DIVISLAB swing trade report?